Trials / Completed
CompletedNCT05784363
A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face
A Prospective, Randomized, Double-blind, Placebo-controlled, Multi-center Exploratory Study to Investigate NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Merz North America, Inc. · Industry
- Sex
- All
- Age
- 21 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the efficacy and safety of NT 201 injections in the treatment of enlarged pores and excessive sebum production in the face.
Detailed description
Eligible subjects will be randomized to one of the two treatment groups: NT 201 group and placebo in order to receive one session of injections with either NT 201 or placebo in the upper face (forehead and cheek area) on Day 1 and followed for about 90 days after treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NT 201 | Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9 percent (%) Sodium Chloride (NaCl). |
| DRUG | Placebo | Solution for injection prepared by reconstitution of powder with 0.9% NaCl. |
Timeline
- Start date
- 2022-10-27
- Primary completion
- 2024-06-17
- Completion
- 2024-07-31
- First posted
- 2023-03-24
- Last updated
- 2024-08-23
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05784363. Inclusion in this directory is not an endorsement.